Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

FORGOTTEN HISTORY: 25 - The Untold Story

WHO issues warning on weight loss drugs

Balanced diet and exercise remain key to losing weight, health body says

The Independent UK

Exclusive-Wegovy, other weight loss drugs ‘no silver bullet’, says WHO amid obesity review

New highly-effective weight loss drugs such as Novo Nordisk's Wegovy are not a “silver bullet” for addressing the rapid rise in global obesity rates, the World Health Organization’s nutrition chief told Reuters, as the agency conducts its first review of obesity management guidelines in more than 20 years.

Reuters

What's behind shortages of Adderall, Ozempic and other meds?

Drug shortages are growing in the United States, and experts see no clear path to resolving them

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Can drugs fix the UK’s adolescent obesity crisis?

A powerful new weight-loss medication may be approved for those aged 12 to 17. But healthcare professionals fear it ignores the underlying socioeconomic causes

The Guardian - UK

Children could be prescribed weight-loss jabs on the NHS

Department of Health asks watchdog to assess effectiveness of giving semaglutide to obese youngsters aged 12 to 17

The Guardian - UK

Doctors issue urgent warning over diabetes drug Ozempic being sold on Facebook Marketplace

The alert comes after an increased number of social media posts, in which users are marketing the drug as a rapid weight loss solution

Chronicle Live

Social Media adds to weight loss craze

GLP-1 agonists are a class of weight loss drug that is going viral on social media — but misinformation is rife

Salon

Read news from The Economist, FT, and more,
with one subscription

A ‘skinny jab’ is no quick fix for obesity – and no excuse to let junk food companies off the hook

Britain should be taxing unhealthy food and clamping down on marketing, says Sarah Boseley, the Guardian’s former health editor

The Guardian - UK

Social media is fueling enthusiasm for new weight loss drugs. Are regulators watching?

Suzette Zuena is her own best advertisement for weight loss.

Tribune News Service

Experts warn new weight loss medications carry long-term concerns

Some doctors, psychologists and eating disorder experts worry these new medications, originally developed to treat diabetes, could become a problem long-term.

Chicago Sun-Times

So, is Wegovy the same as Ozempic? Your need-to-knows about the controversial over-the-counter weight loss drugs

Two experts explain.

Marie Claire

Revealed: maker of Wegovy ‘skinny jab’ is funding NHS weight-loss services

Critics fear conflict of interest as Novo Nordisk helps medics ‘reduce unnecessary barriers’ to treatment for obesity

The Guardian - UK

EU backs use of Novo Nordisk's weight loss drug in adolescents

The European Medicines Agency said on Friday its committee has recommended expanding the use of Danish drugmaker Novo Nordisk's weight loss drug in adolescents aged 12 years and older.

Reuters

How Investors are Capitalizing on the Ozempic and Wegovy Craze

Ozempic and Wegovy started as injectable diabetes treatments. But now, these “appetite suppressants” are being touted as miracle weight loss drugs.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

Stay Forever Young With These 3 Pharmaceutical Stocks

Despite macroeconomic headwinds, the pharmaceutical industry is anticipated to stay buoyed in the foreseeable future, owing to rising healthcare spending. Against this backdrop, we think the strong fundamentals of Novo Nordisk (NVO), Bristol-Myers Squibb (BMY), and Takeda Pharmaceutical (TAK) make them wise portfolio additions. Read on….

Evening Standard

WHO to consider adding obesity drugs to ‘essential’ medicines list

A panel of advisers to the WHO will review requests for drugs to be included next month

ABC News

Relief for diabetes sufferers with fast-acting insulin Fiasp to remain on PBS until September

Fast-acting insulin Fiasp has been a "game changer" for Daniel Webb in managing his type 1 diabetes. The drug was about to be removed from the PBS, but a temporary solution has been found.

The Guardian - UK

‘I skip meals to make my insulin last’: the cost of diabetes in the global south

The three firms that control the insulin market are to cut costs in the US, but elsewhere users can spend all their pay to get the life-saving drug

Get all your
news in one place.

100's of premium titles.
One news app.

Los Angeles Times

Newsom announces $50 million contract to make California’s own brand of insulin

LOS ANGELES — California Gov. Gavin Newsom announced a new $50-million contract with the nonprofit generic drugmaker Civica to produce insulin under the state’s own label during a news conference Saturday in Downey.

The Guardian - UK

‘Skinny jab’ drug firm facing fresh inquiries after ‘serious breaches’ of industry code

Pharmaceutical company behind blockbuster diet jab Wegovy confronts crises on multiple fronts, amid scrutiny of UK activities

Axios

The biggest U.S. pharmaceutical companies are lowering insulin costs to save themselves money

So much for altruism.

Chicago Sun-Times

Anti-obesity drug demand expected to skyrocket, but will insurance cover the cost?

New weight loss drugs can cost more than $1,000 a month, but most health plans don’t cover them.

The Guardian - UK

Firm behind Wegovy slimming jab suspended from UK trade association

Novo Nordisk found to be in breach of ABPI code of practice over sponsored weight-loss courses that promoted its medicines

The Independent UK

Biden drawing contrast to Republicans on lower drug costs

President Joe Biden will highlight the stark differences in how Democrats are tackling skyrocketing drug prices compared to their Republican counterparts as he gears up for an expected reelection announcement

WEKU

Novo Nordisk will cut some U.S. insulin prices by up to 75% starting next year

The Danish drugmaker's move follows a similar announcement by rival Eli Lilly earlier this month. More than 8 million Americans use insulin, according to the American Diabetes Association.

1 … 24 25 26 27

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations